|
gptkbp:instanceOf
|
gptkb:chemical_compound
antidepressant
melatonergic drug
naphthalene derivative
|
|
gptkbp:5-HT2C_antagonist
|
yes
|
|
gptkbp:approvedBy
|
gptkb:European_Union
|
|
gptkbp:ATCCode
|
N06AX22
|
|
gptkbp:bioavailability
|
less than 5%
|
|
gptkbp:brand
|
gptkb:Melitor
gptkb:Thymanax
gptkb:Valdoxan
|
|
gptkbp:CASNumber
|
138112-76-2
|
|
gptkbp:compatibleWith
|
gptkb:Canada
gptkb:Japan
gptkb:United_States
|
|
gptkbp:contraindication
|
hepatic impairment
|
|
gptkbp:developer
|
gptkb:Servier
|
|
gptkbp:eliminationHalfLife
|
1–2 hours
|
|
gptkbp:excretion
|
urine (80%)
|
|
gptkbp:hasMolecularFormula
|
C15H17NO2
|
|
gptkbp:hasSMILES
|
COC1=CC2=C(C=C1)C=CC=C2CCNC(=O)C
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Agomelatine
|
|
gptkbp:indication
|
gptkb:major_depressive_disorder
|
|
gptkbp:IUPACName
|
N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
|
|
gptkbp:KEGGID
|
D07441
|
|
gptkbp:legal_status_(EU)
|
prescription only
|
|
gptkbp:legalStatus
|
not approved
|
|
gptkbp:mechanismOfAction
|
5-HT2C receptor antagonist
melatonin receptor agonist (MT1 and MT2)
|
|
gptkbp:melatonin_receptor_agonist
|
gptkb:MT1
gptkb:MT2
|
|
gptkbp:metabolism
|
liver (CYP1A2, CYP2C9, CYP2C19)
|
|
gptkbp:molecularWeight
|
243.304 g/mol
|
|
gptkbp:monitoring_required
|
liver function tests
|
|
gptkbp:pregnancyCategory
|
gptkb:B3
not assigned
|
|
gptkbp:prescribes
|
gptkb:depression
anxiety (off-label)
sleep disorders (off-label)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2104746
74113
82148
DB06594
|
|
gptkbp:riskFactor
|
liver toxicity
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
increased liver enzymes
|
|
gptkbp:UNII
|
U4F3785M89
|
|
gptkbp:year_of_EU_approval
|
2009
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
gptkb:阿戈美拉汀
|
|
gptkbp:bfsLayer
|
6
|